Floatz logo

Maplirpacept

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Mayo ClinicPhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
(+)-VINCRISTINE
Patrick C. Johnson, MD
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B
Venetoclax
National Cancer Institute (NCI)
Phase 2B
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2B

View all 40 →

Same molecule, other indications

Maplirpacept is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
ALK-positive large B-cell lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →